DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 2, 2007; DOI: 10.1124/dmd.107.014860


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.014860v1
35/7/1081    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, P.
Right arrow Articles by Zhou, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, P.
Right arrow Articles by Zhou, S.


Received for publication January 25, 2007.
Revised March 27, 2007.
Accepted for publication March 28, 2007.

Identification of a Novel Glutathione Conjugate of Flutamide in Incubations with Human Liver Microsomes

Ping Kang 1*, Deepak Dalvie 1, Evan Smith 1, Sue Zhou 1

1 Pfizer

* Address correspondence to: E-mail: ping.kang{at}pfizer.com

Abstract

Flutamide, a nonsteroidal antiandrogen drug widely used in the treatment of prostate cancer, has been associated with rare incidences of hepatotoxicity in patients. It is believed that bioactivation of flutamide and subsequent covalent binding to cellular proteins is responsible for its toxicity. Current in vitro studies were undertaken to probe the P450-mediated bioactivation of flutamide and identify the possible reactive species using reduced glutathione (GSH) as a trapping agent. NADPH- and GSH-supplemented human liver microsomal incubations of flutamide gave rise to a novel GSH conjugate where GSH moiety was conjugated to the flutamide molecule via the amide nitrogen, resulting in a sulfenamide. The structure of the conjugate was characterized by LC-MS/MS and NMR experiments. The conjugate formation was primarily catalyzed by heterologously expressed CYP2C19, CYP1A2, and to a lesser extent by CYP3A4 and CYP3A5. The mechanism for the formation of this conjugate is unknown; however, a tentative bioactivation mechanism involving a P450-catalyzed abstraction of hydrogen atom from the amide nitrogen of flutamide and the subsequent trapping of the nitrogen-centered radical by GSH or GSSG was proposed. Interestingly, the same adduct was formed when flutamide was incubated with human liver microsomes in the presence of GSSG and NADPH. This suggests that P450-mediated oxidation of flutamide via a nitrogen-centered free radical could be one of the several bioactivation pathways of flutamide. Even though the relationship of the GSH conjugate to flutamide-induced toxicity is unknown, the results have revealed the formation of a novel, hitherto unknown, GSH adduct of flutamide.


Key words: bioactivation, glutathione conjugates


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
H. Takakusa, H. Masumoto, H. Yukinaga, C. Makino, S. Nakayama, O. Okazaki, and K. Sudo
Covalent Binding and Tissue Distribution/Retention Assessment of Drugs Associated with Idiosyncratic Drug Toxicity
Drug Metab. Dispos., September 1, 2008; 36(9): 1770 - 1779.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. Kang, D. Dalvie, E. Smith, S. Zhou, A. Deese, and J. A. Nieman
Bioactivation of Flutamide Metabolites by Human Liver Microsomes
Drug Metab. Dispos., July 1, 2008; 36(7): 1425 - 1437.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.